TY  - JOUR
AU  - Blanquez-Martinez, David
AU  - Diaz-Villamarin, Xando
AU  - Antunez-Rodriguez, Alba
AU  - Pozo-Agundo, Ana
AU  - Munoz-avila, Jose Ignacio
AU  - Martinez-Gonzalez, Luis Javier
AU  - Davila-Fajardo, Cristina Lucia
PY  - 2021
DO  - 10.3390/pharmaceutics13111973
UR  - https://hdl.handle.net/10668/26383
T2  - Pharmaceutics
AB  - High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world's population could be nearsighted at the end of this decade. It is characterized by at least 6...
LA  - en
PB  - Mdpi
KW  - myopia
KW  - pharmacogenetic
KW  - genetic polymorphism
KW  - personalized medicine
KW  - ranibizumab
KW  - anti-VEGF
KW  - VEGFA
KW  - CFH
KW  - ARMS2
KW  - Subfoveal choroidal neovascularization
KW  - Complement factor-h
KW  - Randomized clinical-trial
KW  - Anti-vegf treatment
KW  - Macular degeneration
KW  - Pathological myopia
KW  - Intravitreal ranibizumab
KW  - Photodynamic therapy
KW  - Visual prognosis
KW  - Age
TI  - Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
TY  - research article
VL  - 13
ER  -